Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prasugrel: To Be (Approved) Or Not To Be

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA will soon weigh in; the action date for Lilly/Daiichi’s Plavix competitor is June 26.

You may also be interested in...



Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events

Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.

Prasugrel Outperforms Clopidogrel In Head-To-Head Test For Recurrent Events

Lilly and Daiichi Sankyo await Sept. 26 FDA action date for anti-platelet drug slated to take on Bristol’s Plavix.

Prasugrel Delay Shifts Focus To Possible August Advisory Committee

FDA extends user fee date for the novel anti-platelet drug to Sept. 26.

Related Content

Topics

UsernamePublicRestriction

Register

PS067958

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel